Information Sheet on Medication for Opioid Use Disorder

This information sheet links to primary sources, secondary sources that report on multiple primary sources, informed commentary, and reports from our own literature reviews. To aid in creating printable copies with sources, we have primarily posted the link rather than linked the text.

“In the United States, a monthly injectable form of long-acting naltrexone (Vivitrol) was approved in 2010 as a third medication option for opioid addiction treatment. In the United States, opioid substitution therapy and extended release naltrexone are grouped together in the category ‘medication assisted treatment’ (MAT), to distinguish these treatments from abstinence only methods. Less than half a dozen trials of long-acting naltrexone have been published and they show promising results in terms of reducing relapse. There is little long-term data, however, and extended-release naltrexone has not been shown to reduce mortality or disease. It may even increase overdose death risk upon cessation. Vivitrol is not approved in Canada, although it is available under the country’s special access program in reaction to the opioid crisis.”

The Opioid Crisis in North America, Global Commission on Drug Policy, October, 2017

Medication for Opioid Use Disorder

A shortened, printable .pdf of the information sheet is here.

A printable .pdf of the infographic by Laurel Sindewald is here. It is updated from our original post here.

This content is for informational purposes only and is not a substitute for medical or professional advice. Consult a qualified health care professional for personalized medical and professional advice.

Related reports on addictions treatment, addictions recovery, and addictions policy from Handshake Media, Incorporated:

This post was last updated 10/31/17.

Speak Your Mind